Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix
Clinical trial NCT03610581 · TERMINATED
Trial details
- NCT number
- NCT03610581
- Sponsor
- Janssen Vaccines & Prevention B.V.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-27
- Primary completion
- 2020-10-15
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.